8-K
filed August 13, 2021, 7:59 PM ET
ticker TNGX
CIK 0001819133
M&A
confidence high
sentiment neutral
materiality 0.85
Tango Therapeutics completes de-SPAC merger; starts trading on Nasdaq under TNGX
Tango Therapeutics, Inc.
- Merger closed Aug 10, 2021; Old Tango shares converted at ~0.34 share of new common stock per share.
- PIPE investors purchased 18.61M shares at $10.00/share, raising $186.1M in gross proceeds.
- Post-merger, 87,474,258 shares of common stock outstanding and 9,498,725 shares subject to equity awards.
- Common stock began trading on Nasdaq Capital Market on Aug 11, 2021 under ticker TNGX.
- Directors and officers entered into lock-up agreements for 180 days after closing.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lesley Calhoun was appointed as Director at Tango Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mace Rothenberg was appointed as Director at Tango Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Aaron Davis was appointed as Director at Tango Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Alexis Borisy was appointed as Director at Tango Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Malte Peters was appointed as Director at Tango Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barbara Weber was appointed as Director at Tango Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Reid Huber was appointed as Director at Tango Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.